|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- Non-executive Chairman
Peter Allen
Peter joined Proximagen as Chairman in February 2009 and brings a wealth of experience to the role. Peter has held a number of senior roles in the biotechnology industry, having been Chief Financial Officer of Celltech Group plc between 1992 and 2004 and a Non-Executive Director of Acambis plc from July 2008 to September 2008 ahead of its sale to Sanofi Pasteur. He also currently serves as non-executive Chairman on the Boards of ProStrakan Group plc and Chroma Therapeutics Ltd. Peter is a chartered accountant and his early career included financial controller roles at Associated British Ports and L'Oreal (UK).
- Chief Executive Officer
Kenneth Mulvany
Kenneth joined Proximagen in March 2004 as Chief Executive and acts to focus the Company's commitment to deliver novel drugs
and innovative new treatments for Central Nervous System disorders, bringing new hope to patients and value to shareholders.
Prior to joining Proximagen, Kenneth worked in the venture capital markets focused on the technology industry.
Kenneth played key roles in developing several successful high-tech start-ups. He brings 15 years of business leadership and experience to Proximagen.
Kenneth competed in the 1992 America's Cup.
- Finance Director
James Hunter
James joined Proximagen in January 2005 as Financial Controller and was subsequently appointed to the Board in February 2006. James joined the Group after spending six years in the corporate finance team at Ernst & Young where he worked in mergers and acquisitions and corporate restructuring. James has an MBA from the Cranfield School of Management.
- Non-executive Director
Jackie Hunter
Jackie has nearly 30 years drug discovery and development experience. She is currently the Senior Vice President and Head of Science Environment
Development at GlaxoSmithKline (GSK), and until March 2008 she was the Senior Vice President and Head of the Neurology & GI Centre of Excellence for
Drug Discovery (CEDD) at GSK, during which time the CEDD delivered 17 proofs of concept clinical studies with four transitions into late phase development.
- Non-executive Director
Michael Ashton
Michael joined the Board in December 2005. He has more than 30 years experience in the pharmaceutical industry having worked for Merck Inc., Pfizer Inc., Purepac Inc., and most recently, SkyePharmaplc as CEO.
|
|
|
|
|
|
|
